Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 2793 - 2800 of 12086 results
The End Is (Somewhat) Nigh: FDA Begins Rolling Back Enforcement Policies Implemented in Response to the COVID-19 Pandemic
November 16, 2021| Blog| Viewpoint
Journeys from There to Here (The Middle Way)
November 16, 2021| News
Monthly TCPA Digest — November 2021
November 15, 2021| Article| Viewpoint
TCPA Regulatory Update – Rosenworcel Proposes New Robotext Rules, RND Goes Live, and the FCC Sends Cease-and-Desist Letters
November 15, 2021| Article| Viewpoint
DHS Settlement Will Benefit L-2 and H-4 EAD Workers
November 12, 2021| Alert| Viewpoint
The Department of Labor’s ESG Proposed Rule: A Retirement Committee Perspective
November 12, 2021| Blog| Viewpoint
Federal Circuit Affirms Dismissal of Hatch-Waxman Defendants for Lack of Venue and Failure to State a Claim
November 12, 2021| Blog| Viewpoint
Québec’s Updated Privacy Law Complicates Cross-Border Data Flows
November 12, 2021| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|